Logo Logo
Hilfe
Hilfe
Switch Language to English

Peters, Linsey J. F.; Bidzhekov, Kiril; Bonnin-Marquez, Andrea; Sundararaman, Sai Sahana; Huchzermeier, Rosanna; Maas, Sanne L.; Abschlag, Kathrin; Jans, Alexander; Lin, Cheng; Haberbosch, Markus; Jansen, Yvonne; Yu, Baixue; Sluimer, Judith C. ORCID logoORCID: https://orcid.org/0000-0002-0269-4582; Gijbels, Marion J. ORCID logoORCID: https://orcid.org/0000-0002-4906-0384; Jankowski, Joachim ORCID logoORCID: https://orcid.org/0000-0002-4528-2967; Bartneck, Matthias; Biessen, Erik A. L.; Weber, Christian ORCID logoORCID: https://orcid.org/0000-0003-4610-8714; Döring, Yvonne ORCID logoORCID: https://orcid.org/0000-0001-9307-3396 und Vorst, Emiel P. C. van der ORCID logoORCID: https://orcid.org/0000-0001-5771-6278 (2025): MicroRNA-26b−/− augments atherosclerosis, while mimic-loaded nanoparticles reduce atherogenesis. In: Cardiovascular Research [Forthcoming]

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Aims

Increasing evidence has shown that microRNAs (miRs) play a fundamental role in atherosclerosis, but the exact role of various miRs remains elusive. Preliminary data showed that, with a five-fold increase, miR-26b was highly expressed in human atherosclerotic plaques compared to healthy vessels. Therefore, we aimed to determine its cell-specific effects on atherosclerosis development and its therapeutic potential.

Methods and results

We examined the role of miR-26b in atherosclerosis by using whole-body Apoe−/−Mir26b−/− and myeloid cell-specific miR-26b-deficient (LysM-Cre) mice on a Western-type diet (WTD). Atherosclerotic plaque size and phenotype, as well as the phenotype and function of bone marrow-derived macrophages (BMDMs) from Apoe−/−Mir26b−/− mice, were investigated. Lipid nanoparticles (LNPs) served as vehicles for miR-26b mimics to restore miR-26b levels in miR-26b-deficient BMDMs in vitro and in mice in vivo.

Apoe−/−Mir26b−/− mice have a striking 2.8-fold increase in atherosclerotic lesion size in the aortic arch after 12-week WTD, compared to control Apoe−/−, while lesions in the aortic root were unaffected. Consistent with a more advanced plaque phenotype, collagen, smooth muscle cell, and necrotic core content were all significantly increased in plaques from Apoe−/−Mir26b−/− mice, whilst the relative macrophage content was significantly reduced. This phenotype could also be observed in Apoe−/−Mir26b−/− mice after 4-week WTD. Intriguingly, relative plaque size in the arches of Apoe−/−LysmCre+Mir26bfl/fl mice was increased by 2.5-fold, suggesting a role for myeloid-specific miR-26b in atherosclerosis development. Further highlighting its myeloid-specific effects, Apoe−/−Mir26b−/− BMDMs showed an increase in pro-inflammatory cytokine secretion, which could be rescued by LNPs containing miR-26b mimics. MiR-26b pull-down analysis revealed AnnexinA2 as one of the novel targets playing a key role in these effects, which could be validated in BMDMs in vitro. Furthermore, in vivo treatment of Apoe−/−Mir26b−/− mice as well as ex vivo treatment of human plaques with miR-26b-mimic-loaded LNPs demonstrated their therapeutic potential and human relevance, respectively.

Conclusion

Overall, our results clearly demonstrate an atheroprotective role of miR-26b by attenuating lesion formation, mainly by suppressing inflammation and stimulating collagen breakdown. Furthermore, the therapeutic potential of miR-26b mimic-loaded LNPs could be proven, opening up new avenues for miRNA-based treatment options in the future.

Dokument bearbeiten Dokument bearbeiten